Pulse Biosciences Inc Verschuldung / Eigenkapital
Was ist das Verschuldung / Eigenkapital von Pulse Biosciences Inc?
Verschuldung / Eigenkapital von Pulse Biosciences Inc ist 0.33
Was ist die Definition von Verschuldung / Eigenkapital?
Die Verschuldung zu Eigenkapital ist ein Finanzverhältnis, das den relativen Anteil des Eigenkapitals und der Verschuldung angibt, die zur Finanzierung der Vermögenswerte eines Unternehmens verwendet werden.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Verschuldung / Eigenkapital von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Pulse Biosciences Inc
Was macht Pulse Biosciences Inc?
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
Unternehmen mit verschuldung / eigenkapital ähnlich Pulse Biosciences Inc
- Yancoal Australia Ltd hat Verschuldung / Eigenkapital von 0.33
- Yancoal Australia Ltd hat Verschuldung / Eigenkapital von 0.33
- BLB hat Verschuldung / Eigenkapital von 0.33
- Alliance Developpement Capital SIIC hat Verschuldung / Eigenkapital von 0.33
- Yashili International Ltd hat Verschuldung / Eigenkapital von 0.33
- Lion Rock Resources Inc hat Verschuldung / Eigenkapital von 0.33
- Pulse Biosciences Inc hat Verschuldung / Eigenkapital von 0.33
- Sun Hung Kai Properties hat Verschuldung / Eigenkapital von 0.33
- EyePoint Pharmaceuticals Inc hat Verschuldung / Eigenkapital von 0.33
- Multifield International hat Verschuldung / Eigenkapital von 0.33
- Zenith Healthcare hat Verschuldung / Eigenkapital von 0.33
- iShares Trust - iShares Core S&P 500 ETF hat Verschuldung / Eigenkapital von 0.33
- The Peria Karamalai Tea and Produce hat Verschuldung / Eigenkapital von 0.33